PSivida brings in $10.8M from stock sale

07/22/2013 | American City Business Journals

Watertown, Mass.-based biotech pSivida secured $10.8 million from a public stock offering. According to an SEC filing, the money will support further clinical development of Iluvien, an experimental drug for posterior uveitis, and fund pSivida's other research and development programs.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL